Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study)
Status:
Terminated
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This study is aimed to comprehensively establish the biosimilarity/bioquivalence in EPIAO®
and EPREX® in terms of 52-week comparisons in efficacy,safety and immunogenicity.The targeted
population is anaemia patients with chronic renal disease who are naive to epoetin treatment
and not yet on haemodialysis.